🕵️ Connect Biopharma Holdings Ltd ($CNTB)
SEC insider & ownership activity, last 12 months · CIK 1835268 · every row links its SEC filing
Over the last 12 months insiders bought $4.4M with no open-market selling against it. Huang James bought $4.4M in discretionary trades (Mar–May). James Huang trimmed 21.5% → 21.2%; Panacea Innovation Limited trimmed 21.5% → 21.2%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, $4.4M (2 lots) · 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Huang James | 2 | $4.4M | 0 | – | May 29, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 21.2% | 13D | Mar 31, 2026 | filing ↗ | |
| James Huang | 21.2% | 13D | Mar 31, 2026 | filing ↗ | |
| Panacea Innovation Limited | 21.2% | 13D | Mar 31, 2026 | filing ↗ | |
| Panacea Venture Healthcare Fund II, L.P. | 21.2% | 13D | Mar 31, 2026 | filing ↗ | |
| Biofortune Inc. | 10.7% | 13G | Feb 17, 2026 | filing ↗ | |
| Wubin Pan | 9.6% | 13G | Apr 14, 2026 | filing ↗ | |
| Biofortune Inc | 9.5% | 13G | Apr 14, 2026 | filing ↗ | |
| Ikarian Capital, LLC | 8.8% | 13G | Feb 17, 2026 | filing ↗ | |
| Neil Shahrestani | 8.8% | 13G | Feb 17, 2026 | filing ↗ | |
| Wei Zheng | 6.2% | 13G | May 15, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Panacea Innovation Limited | $6.0M | Nov 24, 2025 | filing ↗ |
| Wei Zheng | $2.1M | Nov 21, 2025 | filing ↗ |
| Biofortune Inc | $1.2M | Nov 18, 2025 | filing ↗ |
| Wei Zheng | $306K | Oct 1, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Earnings (2.02) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 23, 2026 | filing ↗ |
| Other events (8.01) | Apr 23, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 23, 2026 | filing ↗ |
| Earnings (2.02) | Mar 31, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 31, 2026 | filing ↗ |
| Material agreement (1.01) | Mar 29, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Mar 29, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 29, 2026 | filing ↗ |
| Other events (8.01) | Mar 29, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 29, 2026 | filing ↗ |
| Officer/director changes (5.02) | Dec 17, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 17, 2025 | filing ↗ |
| Earnings (2.02) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Sep 16, 2025 | filing ↗ |
| Earnings (2.02) | Aug 13, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 13, 2025 | filing ↗ |